Humanigen

aka KaloBios Pharmaceuticals, Humanigen, Inc., NASDAQ:HGEN

Humanigen, formerly KaloBios, made lenzilumab, an antibody that neutralises GM-CSF to blunt the cytokine storms of CAR-T therapy and COVID-19, before filing for bankruptcy in 2024.

Humanigen developed lenzilumab (KB003), a humanised antibody against granulocyte-macrophage colony-stimulating factor. It was studied to prevent cytokine release syndrome and neurotoxicity in patients receiving axicabtagene ciloleucel for lymphoma, in chronic myelomonocytic leukaemia, and in a large randomised trial in hospitalised COVID-19 patients, where the FDA declined emergency authorisation. The company, once KaloBios Pharmaceuticals, filed for Chapter 11 bankruptcy in January 2024.

Headquarters

Short Hills, New Jersey, US

Scorecard

All companies

#452of 1181 companies, score 3

phase 1/2 +1
modalities +2

0 approved, 0 in phase 3, 1 earlier, 0 targets, 0 registry studies. Formula on the scorecards page.

Type

biotech

Stage

Wound down

Products

1top

Phase 2Humanised anti-GM-CSF monoclonal antibody

Lenzilumab

Lenzilumab is an antibody that soaks up GM-CSF, a growth signal that chronic myelomonocytic leukaemia cells with RAS mutations are unusually sensitive to. It is being tested with azacitidine in this leukaemia.

Connected